Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for rare diseases to ensure that none of the 30 million people in Europe living with rare diseases are left behind by the start of a new decade. As part of…
Following a review of available clinical data, Immunovant has announced plans to resume clinical testing of the investigational medication IMVT-1401 in myasthenia gravis (MG) and other autoimmune conditions. Following discussions with regulatory agencies, the company is planning to launch a potentially pivotal trial of IMVT-1401 in…
Ahead of this year’s Rare Disease Week on Capitol Hill, held virtually July 14–22, the EveryLife Foundation will award grants to top advocates of rare disease organizations who participate in the week’s pre-events. The top 50 point-earners will be eligible to win $1,000 to $5,000in grants, totaling up…
From contributing to an interactive activities map to taking up challenges and advocating for local proclamations, supporters are set to mark Myasthenia Gravis Awareness Month, held each June. The aim is to raise global awareness among the general public, as well as among policymakers, public authorities, industry representatives, scientists, and…
Thymectomy – surgical removal of the thymus gland — may be a better option for treating patients with early-onset non-thymomatous myasthenia gravis (MG), a study has found. According to study data, the surgical procedure did not confer an added benefit over non-invasive treatment options for patients with late-onset disease.
A micro RNA molecule called miR-146a was found at high levels in the blood of patients with myasthenia gravis (MG), and this is thought to contribute to disease development, a single-site study suggests. The findings put forward miR-146a as “a suitable candidate marker for diagnosing MG,” the researchers wrote.
The rare case of a female patient who developed myasthenia gravis (MG) in association with Hodgkin’s lymphoma, a type of blood cancer, highlighted the link between these conditions and the therapeutic challenge they pose. Her case was described…
Patients with myasthenia gravis (MG) and self-reactive antibodies against the muscle-specific kinase (MuSK) protein are more likely to have poorer outcomes when experiencing a myasthenic crisis than other MG patients, a study suggests. Outcomes linked to MuSK antibody production include longer periods of hospitalization or admittance to intensive care,…
A new type of plasma exchange treatment, called double-filtration plasmapheresis (DFPP), may be effective and safe for short-term relief of myasthenia gravis (MG) symptoms, a review study has found. These findings may have important clinical implications, especially for patients with severe or critical MG, the researchers noted. The review,…
People with myasthenia gravis (MG) who have difficulty swallowing are more likely to have poor clinical outcomes, according to a recent study. Data from the study also indicates that low levels of albumin — a protein found in the blood that helps transporting hormones and other key molecules in…
Get regular updates to your inbox.